Полиморфизм ферментов метаболизма ксенобиотиков и антиоксидантной защиты и развитие гепатотоксических реакций у больных туберкулёзом легких
Диссертация
При исследовании причин возникновениягепатотоксичности большое внимание уделяется-метаболизму ПТП. Известно, что биологические эффекты химических соединений в значительной мере зависят от метаболизма, т.к. на этом этапе меняется биологическая активность вещества (Parkinson А., 2001). Метаболизм многих лекарственных соединений, осуществляемый ферментами биотрансформации ксенобиотиков (ФБК… Читать ещё >
Список литературы
- Белиловский Е.М., Борисов С. Е., Скачкова Е. И., Сон И.М., Галкин В. Б., ¦ Данилова И. Д., Пашкевич Д. Д. Туберкулёз в Российской Федерации 2009 г.
- Аналитический обзор статистических показателей по туберкулёзу, используемых в Российской Федерации. Москва, 2010. — С. 22 — 60.
- Вестник Казанского технологического университета. — 2006. — № 5. — С. 32 — 40.
- Григорян В'. Г. Влияние этионамида и пиразинамида на ультраструктуру клеток печени кроликов / Григорян В. Г., Салов В: Ф. // Проблемы туберкулеза-. -1976.-№ 8.-С. 55−60.
- Кайгородова Е.В. Роль редокс-чувствительных МАР-киназ ЖК и р38 в дизрегуляции апоптоза мононуклеарных лейкоцитов при окислительном стрессе // Дисс. канд. мед. наук: // СибГМУ. Томск, 2008. — 137 с.
- Колпакова Т.А. Осложнения антибактериальной терапии у больных туберкулезом легких с сопутствующими заболеваниями^// Дисс. докт. мед. наук: Новосибирск, 2002. 288 с.
- Липкина Г. С. Гистологическое и электронномикроскопическое изучение действия рифампицина на органы крыс / Липкина Г. С., Фомина В. А. // Антибиотики. 1973. — Т. 18, № 7. — С. 639 — 645.
- Макарова С. И. Показатели атопии у детей с бронхиальной астмой возрастают с накоплением нуль-аллелей глутатион-8-трансферазы М1 / Макарова С.
- И., Сафронова, О. Г., Вавилин, В. А., Батычко О. А., Гавалов С. М. // Бюллетень эксперимен. Биол. и мед. 2004. — Т. 13 8, № 11. — С. 520 — 522.
- Малюк В. И. Новые данные о биохимических механизмах туберкулезного процесса и коррекция их нарушений этиопатогенетическими препаратами. // Проблемы туберкулеза. 1984. -№ 11. — С. 61 — 64.
- Маниатис Т., Фрич Э., Сэмбрук Дж. Методы генетической инженерии. Молекулярное клонирование. Москва: Мир, 1984. — 480 с.
- Меныцикова Е.Б., Ланкин В. З., Зенков Н. К., Бондарь H.A., Круговых Н. Ф., Труфакин В. А. Окислительный стресс. Прооксиданты и антиоксиданты. — Москва: Фирма «Слово», 2006. 556 с.
- Мишин В.Ю., Чуканов В .И., Григорьев Ю. Г. Побочное действие противотуберкулёзных препаратов при стандартных и индивидуализированных режимах химиотерапии. Москва: Издательство «Компьютербург», 2004. — 208 с.
- Мордык A.B. Влияние неблагополучных побочных реакций химиотерапии на показатели качества жизни больных инфильтративным туберкулёзом лёгких / Мордык A.B. Антропова В. В. // Проблемы туберкулеза и болезней лёгких. -2008.-№ 9.-С. 44−46.
- Никишина М.В. Исследование полиморфизма генов ариламин N-ацетилтрансфераз и ассоциации полиморфных вариантов с раком легкого у европеоидов г. Новосибирска: Дисс. канд. биол. наук: Новосибирск, 2007. 125 с.
- Полунина Т. Е. Лекарственные поражения печени. // Лечащий врач. -2005. -№ 3. — С. 8 — 13.
- Сельцовский П.П. Анализ особенностей эпидемической ситуации по туберкулёзу и системы защиты населения от туберкулёза в г. Москве / Сельцовский П. П., Рыбка Л. И., Кочетова Е. Я., Горбунов A.B. // Туберкулёз и болезни лёгких.-2011.-№ 6.-С. 10−16.
- Скакун Н. П. Сравнительная гепатотоксичность изониазида, рифампицина-и этамбутола / Скакун Н. П., Табачук О. Е. // Проблемы туберкулеза. — 1991. — № 10. — С. 77 — 79.
- Скакун Н. П. Эффективность антиоксидантов при поражении печени изо-ниазидом / Скакун Н. П., Шманько В. В. // Фармакология и токсикология. — 1986. Т.49, № 4. — С. 86 — 89.
- Скачкова Е.И. О программе государственных гарантий' оказания гражданам России бесплатной ^ медицинской помощи в противотуберкулёзных учреждениях/ Скачкова Е. И., Нечаева О. Б. // Проблемы туберкулеза. 2008. — № 8. -С. 17:
- Сливка Ю. И- О гепатотоксическом действии сочетаний" пиразинамида с изониазидом и рифампицином / Сливка Ю: И., Климнюк Е. В>, Табачук О. Е. // Проблемы туберкулеза. — 1989. -№ 4. С. 39 — 42.
- Фисенко В. Противотуберкулезные средства: принципы действия, побочные эффекты и перспективы создания новых лекарственных препаратов. // Врач. 2006. — № 12. — С. 30 — 34.
- Холодов JI. Е., Яковлев В. П. Клиническая фармакокинетика. Москва: Медицина, 1985. — 464 с.
- Шилова М.В. Противотуберкулёзные стационары России (потребность, перспективы развития) // Проблемы туберкулеза и болезней лёгких. — 2009. — № 5.-С.9−15.
- Ю В. В. Факторы риска развития гепатоксических эффектов при проведении противотуберкулезной химиотерапии у пациентов из Азиатских стран. // Международный журнал по туберкулезу и заболеваниям легких. — 2006. — Вып. 1,№ 2.-С. 74−77.
- Adler V. Regulation of JNK signaling by GSTp / Adler V., Yin Z., Fuchs S. Y., Benezra M., Rosario L., Tew K. D., Pincus M. R., Sardana M., Henderson C. J., Wolf C. R., Davis R. J., Ronai Z. // EMBO J. 1999 — V. 18, N. 5. — P. 1321 — 1334.
- Agundez J.A. Glutatione S-transferase GSTT1 and GSTM1 allozymes: beyond null alleles / Agundez J.A., Ladero J. M, // Pharmacogenomics. 2008. — V. 9, N. 3. -P. 359−363.
- American Thoracic Society / Centers for Disease Control and Prevention / Infectious Diseases Society of America: Treatment of Tuberculosis //Am. J. Crit. Care Med. 2003. — V. 167. — P. 603 — 662.
- Arisawa T. Nrf2 gene promoter polymorphism and gastric carcinogenesis / Arisawa Т., Tahara Т., Shibata Т., Nagasaka M., Nakamura M., Kamiya Y., Fujita H.,
- Yoshioka D., Okubo M., Hirata I., Nakano H. // Hepatogastroenterology. 2008. -V. 55, N. 82−83. — P. 750 — 754.
- Bernardini S. Modulation of GST Pl-1 activity by polymerization during apop-tosis / Bernardini S., Bernassola F., Cortese C., Ballerini S., Melino G., Motti C., Bel-lincampi L., Iori R, Federici G. // J. Cell Biochem. 2000. V. 77, N. 4. — P.645 -653.
- A.A., Cederbaum A.T. // Annu. Rev. Pharmacol. Toxicol. 2004 — V. 44. — P. 27 -42*.
- Chatterjee S. GSTT1 and GSTM1 gene deletions are not associated with hepato-toxicity caused by antitubercular drugs / Chatterjee S., Lyle N., Mandai A., Kundu S. // J. Clin. Pharm. Ther. 2010. — V. 35, N. 4. — P. 465 — 470:
- Chien J.Y. Pharmacokinetic consequences of induction of CYP2E1 by ligand stabilization / Chien J.Y., Thummel K.E., Slattery J.T. // Drug Metab Dispos. 1997.-V. 25, N. 10. P. 1165 -1175.
- Choi S.Y. Optic neuropathy associated with ethambutol in Koreans / Choi S.Y., Hwang J.M. // Korean J. Ophthalmol. 1997. — V. 11, N. 2. — P. 106 — 110.
- Cynamon M.IT. High-Dose Isoniazid Therapy for- Isoniazid-Resistant Murine Mycobacterium tuberculosis Infection / Cynamon M.H., Zhang Y., Harpster T., Cheng S., Destefano M.S. // Antimicrob. Agents Chemother. 1999. — V. 43, N. 12. — P. 2922 — 2924.
- De Rosa HJ: The effect, of pyrazinamide and rifampicin on isoniazid metabolism in rats / DerRbsaTiiJi, Baldan №M, Brunetti I.L., Ximcnes V.F., Machado R. Gi //Biopharm^ DrugDispos. 2007. — V. 28, N. 6. — Pr 291 — 296.
- Deguchi T. Correlation between acetylator phenotypes and genotypes of polymorphic arylamine N-acetyltransferase in human liver / Deguchi T., Mashimo Ml, Suzuki T.//J. Biol. Chem.- 1990.-V. 265.-P. 12 757- 12 760.
- Deka M. Role of CYP2E1 gene polymorphisms association with hepatitis risk in Northeast India / Deka M, Bose M, Baruah B, Bose PD", Medhi S, Bose S, Saikia A, Kar P: // World J. Gastroenterol. 2010 V. 16, N. 38: — P. 4800- 4808.
- Desta Z. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A / Desta Z., Soukhova N.V., Flockhart D.A. Antimicrob. Agents Chemother. 2001. — V. 45, N. 2. -P. 382 -392.
- Doll M-A. Codominant expression of N-acetylation and O-acetylation activities catalyzed by N-acetyltransferase 2 in human hepatocytes. Doll M.A., Zang Y., Moel-ler T., I-Iein D. W. J. Pharmacol. Exp. Ther. 2010. -V. 334, N. 2. -P. 540−544.
- Donald P.R. Early Bactericidal Activity of Isoniasid Related to Its Dose Size in Pulmonary Tuberculosis / Donald P.R., Sirgel F.A., Botha F.J., Seifart H.I., Parkin
- D.P., Vandenplas M.L., Van de Wal B.W., Maritz J.S., Mitchison D.A. // Amer. Jour. Crit. Care Med. 1997. — V. 156, N. 3, Pt. 1. — P. 895 — 900.
- Dossing M. Liver injury during antituberculosis treatment: an 11-year study / D0ssing M., Wilcke J.T., Askgaard D.S., Nybo>B. // Tuber. Lung Dis. 1996. -V.77, N. 4.-P. 335−340.
- Du Toit L.C. Tuberculosis chemotherapy: current drug delivery approaches / Du Toit L.C., Pillay V., Danckwerts M.P. // Respiratory research. 2006. — V. 7, N. 1. -P. 118−136.
- Eliasson E. Substrate-, hormone-, and cAMP-regulated cytochrome P450 degradation / Eliasson E., Johansson I., Ingelman-Sundberg M. // Proc. Natl. Acad. Sei. U S A. -1990. V. 87, N. 8. — P. 3225 — 3229.
- Ellard G.A. Absorption, metabolism and excretion of pyrazinamide in man. // Tubercle. 1969. -V. 50, N. 2. — P. 144 — 158.
- Ergul Y. Effect of vitamin C on oxidative liver injury due to isoniazid in rats / Ergul Y., Erkan T., Uzun H., Gene H., Altug T., Erginoz E. // Pediatr. Int. 2010. -V. 52, N. l.-P. 69−74.
- Ernstgard L. Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 activity / Ernstgard L., Warholm M., Johanson G. // Br. J. Clin. Pharmacol. -2004. V. 58, N. 2. — P. 190 — 200.
- Fairbrother K.S. Detection and characterization of novel polymorphisms in the CYP2E1 gene / Fairbrother K.S., Grove J., de Waziers I., Steimel D.T., Day C.P., Crespi C.L., Daly A.K. // Pharmacogenetics. 1998. — V. 8, N. 6. — P. 543 — 552.
- Forbes M. Effect of ethambutol on Mycobacteria / Forbes M., Peets E.A., Kuck N.A.//Ann. N. Y. Acad. Sci. 1966. — V. 135, N.2-P. 726−731.
- Forget E. Adverse reactions to first-line antituberculosis drugs / Forget E., Men-zies D. // Expert Opin. Drug Saf. 2006. — V. 5, N. 2 — P. 231 — 249.
- Garcia-Martin E. Interethnic and intraethnic variability of NAT2 single nucleotide polymorphisms. // Curr. Drug Metab. 2008. — V. 9, N. 6. — P. 487 — 497.
- Gonzalez F.J. Cytochrome P450 and xenobiotic receptor humanized mice. / Gonzalez F.J., Yu A.M. // Annu. Rev. Pharmacol. Toxicol. 2006. — V. 46. — P. 41 -64.
- Guengerich F.P. Cytochromes P450, drugs, and diseases. // Mol. Interv. — 2003.. —V. 3, N. 4.-P. 194−204.
- Guengerich F.P. Reactions and significance of cytochrome P-450 enzymes. // J. Biol. Chem. 1991. — V. 266, N. 16. — P. 10 019 — 10 022.
- Gunawan B.K. c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity / Gunawan B.K., Liu Z.X., Han D., Hanawa N., Gaarde W.A., Kaplowitz N. // Gastroenterology. 2006. — V. 131, N. 1. — P. 165 — 178.
- Guy C.A. Promoter polymorphisms in glutathione-S-transferase genes affect transcription / Guy C.A., Hoogendoorn B., Smith S.K., Coleman S., O’Donovan M.C., Buckland P.R. // Pharmacogenetics. -2004. -V. 14, N: 1.-P. 45−51.
- Hakkola J. Mechanisms of down-regulation of CYP2E1 expression by inflammatory cytokines in rat hepatoma cells / Hakkola J., Hu Y., Ingelman-Sundberg M. // J. Pharmacol. Exp. Ther. 2003. -V. 304, N. 3. — P. 1048 — 1054.
- Hayashi S. Genetic polymorphisms in the 5'-flanking region change transcriptional regulation of the human cytochrome P450IIE1 gene / Hayashi S., Watanabe J.,
- Kawajiri K. // J. Biochem. 1991. — V. 110, N. 4. — P. 559 — 565.
- Hayes J.D. Glutathione transferases / Hayes J.D., Flanagan J.U., Jowsey I.R. // Annu. Rev. Pharmacol. Toxicol. 2005. — V.45. — P. 51 — 88.
- Hein D.W. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexicities of personalized medicine. // Expert Opin. Drug Metab. Toxicol. 2009. — V. 5, N. 4. — P. 353 — 366.
- Hickman D. Chromosomal localization^ of human genes for arylamine N-acetyltransferase / Hickman D., Risch A., Buckle V., Spurr N.K., Jeremiah S.J., McCarthy A., Sim E. // Biochem J. 1994. — V. 297, Pt, 3. — P. 441 — 445.
- Hickman D. Enzyme kinetic properties of human recombinant arylamine N-acetyltransferase 2 allotypic variants expressed in esherichia coli / Hickman D., Palamanda J.R., Unadkat J.D., Sim E. // Biochem. Pharmacol. 1995. — V. 50, N. 5. -P. 697−703.
- Hickman D. N-acetyltransferase polymorphism. Comparison of phenotype and genotype in humans / Hickman D., Sim E. // Biochem Pharmacol. 1991. — V. 42, N. 5.-P. 1007−1014.
- Hu Y. Genetic polymorphism of human CYP2E1: characterization of two variant alleles / Hu Y., Oscarson M., Johansson I., Yue Q.Y., Dahl M.L., Tabone M., Arinco S., Albano E., Ingelman-Sundberg M. // Мої. Pharmacol. 1997. — V. 51, N. 3.-P. 370−376.
- Huang Y.S. Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced, hepatitis / Huang Y.S., Chern H.D., Su W.J., Wu J.C., Chang S.C., Chiang’C.H., Chang F.Y., Lee*S.D: // Hepatology. 2003. — V. 37, N. 4. — P. 924 — 930.
- Huang Y.S. Genetic polymorphisms of drug-metabolizing enzymes and the susceptibility to antituberculosis drug-induced liver injury. // Expert Opin. Drug Metab. Toxicol. 2007. — V. 3, N. 1. — P.1 — 8.
- Huang Y.S. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis / Huang Y.S., Chern H.D., Su• WJ. // Hepatology. 2002. — V.35. -N.4. — P.883 — 889.
- Ito K. Manganese-mediated oxidative damage of cellular and isolated DNA by isoniazid and related hydrazines: non-Fenton-type hydroxyl radical formation / Ito K., Yamamoto K., Kawanishi S. II Biochemistry. 1992. — V. 31, N. 46 — P. l 1606 -11 613.
- Khalili H. Is there any difference between acetylator phenotypes in tuberculosis patients and healthy subjects? / Khalili H., Dashti-Khavidaki S., Amini M., Mahjub R., Hajiabdolbaghi M. // Eur. J. Clin. Pharmacol. 2010. — V. 66, N. 3. — 261 — 267.
- Kim R.B. Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to- CYP2E1 genetic polymorphisms / Kim R.B., O’Shea D. // Clin. Pharmacol. Ther. 1995. — V. 57, N. 6. — P. 645 — 655.
- Kim S.H. GSTT and GSTM1 null mutations and adverse reactions induced by antituberculosis drugs in Koreans / Kim S.H., Kim S.H., Yoon H.J., Shin D.H., Park
- S.S., Kim Y.S., Park J.S., Jee Y.K. // Tuberculosis (Edinb). 2010. — V. 90, N. 1 — P. 39−43.
- Kita T. N-acetyltransferase 2 Genotype Correlated with Isoniazid Acetylation in Japanese Tuberculous Patients / Kita T., Tanigawara Y., Chikazawa S. // Biol. Pharm. Bull. 2001. — V. 24, N. 5. — P: 544 — 549.
- Lacroix C. Pharmacokinetics of pyrazinamide and its metabolites in healthy subjects / Lacroix C., Hoang T.P., Nouveau J., Guyonnaud C., Laine G., Duwoos H., La-font O. // Eur. J. Clin. Pharmacol. 1989. — V. 36, N. 4. — P. 395 — 400.
- Le Marchand L. Predictors of N-acetyltransferase activity: should caffeine phe-notyping and NAT2 genotyping be used interchangeably in epidemiological studies? / Le Marchand L., Sivaraman L., Franke A.A., Custer L.J., Wilkens L.R., Lau A.F.,
- Cooney R.V. // Cancer Epidemiol. Biomarkers Prev. 1996. — V. 5, N. 6. — P. 449 -455.
- Lee B.H. Inactive hepatitis B surface antigen carrier state and: hepatotoxicity during antituberculosis chemotherapy / Lee B.H., Koh W.J., Choi M.S., Suh G.Y., Chung M.P., Kim H, Kwon OiJ. // Chest- — 2005-.— V. 127,.N. 4. — P. 1304−1311.
- Lee S.W. NAT2 and-CYP2E1 polymorphisms and susceptibility to first-line antituberculosis drug-induced hepatitis / Lee: S.W., Chung L.S., Huang H. IL, Chuang T.Y., Liou Y.H., Wu L.S. U Int? J. Tuberc. Lung Dis. 2010. — V. 14, N. 5.- P. 622 -626.
- Lee S.Y. Complete sequencing of a genetic polymorphism in NAT2 in the Korean population / Lee S.Y., Lee K.A., Ki C.S., Kwon O .J., Kim H.J., Chung M.P., Suh G.Y., Kim LW. H Clin. Chem. 2002. — V.48, N. .5. — P: 775 — 111.
- Leff M.A. Novel humamN-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype / Leff M.A., Fretland A.J., Doll M.A., Hein D.W. H I. Biol. Chem.- 1999.-V. 274, N. 49.-34 519−34 522. '
- Leist M. Intracellular adenosine triphosphate (ATP) concentration: a switch in the decision between apoptosis and necrosis / Leist M., Single B., Castoldi A.F., Kiihnle S., NicoteraP. // J. Exp. Med. — 1997. — V. 185, N. 8.-P. 1481−1486.
- Levy S. The role of c-jun phosphorylation in EpRE activation of phase II genes / Levy S., Jaiswal A.K., Forman H.J. // Free Radic. Bio. Med. 2009i — V. 47, N. 8. -P.l 172−1179.
- Loos U. Pharmacokinetics of oral and intravenous rifampicin during chronic administration / Loos U., Musch E., Jensen J.C., Mikus G, Schwabe H.K., Eichelbaum M. // Klin. Wochenschr. 1985. — V. 63, N. 23. — P. 1205 — 1211.
- Lum A. A simple mouthwash method for obtaining genomic DNA in? molecular epidemiological studies / Lum A., Le Marchand L. // Cancer Epidemiol. Biomarkers Prev. 1998. — V. 7, N. 8. — P. 719 — 724.
- Mainwaring G.W. The distribution of theta-class glutathione S-transferases in the liver and lung of mouse, rat and human / Mainwaring G.W., Williams S.M., Foster J.R., Tugwood J., Green T. // Biochem J. 1996. — V. 318, Pt. 1. — P. 297 — 303.
- Makarova S.I. Human N-Acetytransferases and Drug-Induced Hepatotoxicity // Curr. Drug Metab. 2008. — V. 9, N. 6. — P. 538 — 545.
- Makhlouf H.A. A prospective study of antituberculous drug-induced hepatotoxicity in an area endemic for liver diseases / Makhlouf H.A., Helmy A., Fawzy E., El-Attar M., Rashed H.A. // Hepatol. Int. 2008. — V. 2, N. 3 — P. 353 — 360.
- Malhi H. Cellular and molecular mechanisms of liver injury / Malhi H., Gores G.J. // Gastroenterology. 2008. — V. 134, N. 6. — P. 1641 — 1654.
- Masjedi M.R. Chromosomal aberrations and micronuclei in lymphocytes of patients before and after exposure to anti-tuberculosis drugs / Masjedi M.R., Heidary A., Mohammadi F., Velayati A.A., Dokouhaki P. // Mutagenesis. 2000. — V. 15, N. 6.-P. 489−494-
- MattesrW.B. Quantitative reverse transcriptase/PCR assay for the measurement of induction in cultured hepatocytes / Mattes: W.B., Li A.P. // Chem. Biol- Interact. — 1997.-V. 107, N. 1−2,P. 47−61.
- Meyer D.J. Theta, a new class of glutathione transferases purified from rat and man / Meyer D.J., Coles B., Pemble S.E., Gilmore K. S-, Fraser G.M., Ketterer B. // Biochem. J. 1991.-V. 274, Pt, 2: — P. 409−414.
- Morel Y. A repressive cross-regulation between catalytic and promoter activities of the CYP1A1 and CYP2E1 genes: role of H202 / Morel Y., de Waziers I, Barouki R. // Mol. Pharmacol. 2000. — V. 57, N. 6. — P. 1158 — 1164. ff, «
- Morike K. Identification of N2 as a metabolite of acetylhydrazine in the rat / Morike K., Koch M., Fritz P., Urban W., Eichelbaum M. // Arch. Toxicol. 1996. -V. 70, N. 5. -P. 300−305.
- Moyer A.M. Glutathione S-Transferase PI: Gene Sequence Variation and Functional Genomic Studies / Moyer A.M., Salavaggione O.E., Wu T.Y., Moon I., Eckloff
- B.W., Hildebrandt M.A., Schaid D.J., Wieben E.D., Weinshilboum R.M. // Cancer Res. 2008. — V. 68, N. 12. — P. 4791 — 4801*.
- Neafsey P. Genetic polymorphism in CYP2E1: Population distribution of CYP2E1 activity / Neafsey P., Ginsberg G., Hattis D., Johns D.O., Guyton K.Z., Sonawane B. // J. Toxicol. Environ. Health B. Crit. Rev. 2009. — V. 12, N. 5−6. — P. 362−388.
- Nelson S.D. Isoniazid and iproniazid: activation of metabolites to toxic intermediates in man and rat / Nelson S.D., Mitchell J.R., Timbrell J.A., Snodgrass W.R., Corcoran G.B. 3rd. // Science. 1976. — V. 193, N. 4256. — P. 901 — 903.
- Ning B. Human glutathione S-transferase A2 polymorphisms: variant expression, distribution in prostate cancer cases/controls and a novel form / Ning B., Wang
- C., Morel F., Nowell S., Ratnasinghe D.L., Carter W!, Kadlubar F.F., Coles B. // Pharmacogenetics. 2004. — V. 14, N. 1. — P. 35 — 44.
- Nishimura M. Tissue-Specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and Phase II metabolizing enzymes / Nishimura M., Naito S. // Drug Metab. Pharmacokinet. 2006. — V. 21, N. 5. — P.• 357−374.
- Nishimura Y. Inhibitory effect of antituberculosis drugs on human cytochrome P450-mediated activities / Nishimura Y., Kurata N., Sakurai E., Yasuhara H. // J. Pharmacol. Sci. 2004. — V. 96, N. 3. — P. 293 — 300:
- Novak R.F. The alcohol-inducible form of cytochrome P450 (CYP 2E1): role in toxicology and regulation of expression / Novak R.F., Woodcraft K. J. // Arch. Pharm.
- Res. 2000. — V. 23, N. 4. — P. 267 — 282.
- Pande J.N. Risk factors for hepatotoxicity from antituberculosis drugs: a case-control study / Pande J.N., Singh S.P., Khilnani G.C., Khilnani S., Tandon R.K. // Thorax. -1996. -V. 51, N. 2. P. 132 — 136.
- Parkinson A. Disposition of xenobiotics // Casarett and Doull’s Toxicology. The basic science of poisons. New York. — 2001. — P. 133 — 224.
- Powell H. Expression of cytochrome P4502E1 in human liver: assessment by mRNA, genotype and phenotype / Powell H., Kitteringham N.R., Pirmohamed M., Smith D.A., Park B.K. // Pharmacogenetics. 1998. — V. 8, N. 5. — P. 411 — 421.
- Qiu L.O. Suppression of cytochrome P450 2E1 promoter activity by interferon-gamma1 and loss of response due to the -71G>T nucleotide polymorphism of the CYP2E1*7B allele / Qiu L.O., Linder M.W., Antonino-Green D.M., Valdes RJr. // J.
- Pharmacol. Exp. Ther. 2004. — V. 308, N. 1. — P. 284 — 288.
- Rana S.V. Role of N-acetylcysteine in rifampicin-induced hepatic injury of young rats / Rana S.V., Attri S., Vaiphei K., Pal R., Attn A., Singh K. // World J. Gastroenterol. 2006. — V.12, N. 2. — P. 287 — 291.
- Raucy J.L. Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes / Raucy J.L., Lasker J'., Ozaki K., Zoleta V. // Toxicol. Sci. 2004. — V. 79, N. 2. — P. 233 — 241.
- Rawat R. The isoniasid-NAD adduct is a slow, tight-binding inhibitor of InhA,, the Mycobacterium tuberculosis enoyl reductase: Adduct affinity and drug resistance
- Rawat R., Whitty A., Peter J.T. // Proc. Nat. Acad. Sci. USA. 2003. — V. 100, N. 25.-P. 13 881 -13 886.
- Reeves P.T. In vivo mechanisms for the enhanced acetylation of sulfamethazine in the rabbit after hydrocortisone treatment / Reeves P.T., Minchin R.F., Ilett K.F. // J. Pharmacol. Exp. Ther. 1989. — V. 248, N. 1. — P. 348 — 352.
- Riesbeck K. Cyprofloxacin does not inhibit mitochondriar functions but otherantibiotics. do / Riesbeck K., Bredberg A., Forsgren A. // Antimicrob. Agents Chemother. 1990.-V. 34, N. l.-P. 167−169.
- Robin M.A. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis / Robin M.A., Le Roy M., Descatoire V., Pes-sayre D. // J. Hepatol. 1997. — V. 26, Suppl. 1. — P. 23 — 30.
- Rodrigues-Lima F. Effect of environmental substances on the activity of arylamine N-acetyltransferases / Rodrigues-Lima F., Dairou J., Dupret J.M. // Curr. Drug Metab. 2008. — V. 9, N. 6. — P. 505 — 509.
- Roy P.D. Pharmakogenomics of anti-TB drugs-related hepatotoxicity / Roy P.D., Majumder M., Roy B. // Pharmacogenomics. 2008. — V. 9, N. 3. — P. 311 -321.
- Runge-Morris M. Hydrazine-mediated DNA damage: role of hemoprotein, electron transport, and organic free radicals / Runge-Morris M., Wu N., Novak R.F. // Toxicol. Appl. Pharmacol. 1994. — V. 125, N. 1. — P. 123 — 132.
- Sarich T.C. Role of hydrazine in the mechanism of isoniazid hepatotoxicity in' rabbits / Sarich T.G., Youssefi M., Zhou T., Adams S.P., Wall R.A., Wright J.M. // Arch. Toxicol. 1996. — V. 70, N. 12. — P. 835 — 840.
- Schaberg T. Risk factors for side-effects of isoniazid, rifampin and pyrazinamide in patients hospitalized for pulmonary tuberculosis / Schaberg T., Rebhan K., Lode H. //Eur. Respir. J. 1996. — V. 9, N. 10. — P. 2026 — 2030.
- Scholar E.M., Pratt W.B. The antimicrobial drugs 2nd. ed // Oxford Univ. Press. -New York. 2000.
- Vorachek W. R., Pero R.W., Pearson W.R. II Proc. Natl. Acad. Sci. USA. 1988. -V. 85, N. 19. — P. 7293 — 7297.
- Seidegard J. The role of human glutathione transferases- and epoxide hydrolases in the metabolism of xenobiotics / Seidegard J, Ekstrom G. // Environ. Health Per-spect. 1997. — V.105, Suppl. 4. -P. 791 — 799.
- Seifart HJi Population screening for isoniazid acetylator phenotype / Seifart H: I., Parkin D.P., Botha F.J., Donald P.R., Van Der Walt B.J. // Pharmacoepidemiol. Drug Saf.- 2001. V. 10, N. 2. — P. 127- 134.
- Sendo T. Metabolic hydrolysis, of isoniazid by subcellular fractions of rat liver / Sendo T., Noda A., Nodall., Hsu K.Y., Yamamoto Y. II J: UOEH. 1984. — V. 6, N. 3. -Pi 249- 255.
- Sim E. An update on genetic, structural and functional studies of arylamine N-acetyltransferases in eucaryotes and. procaryotes / Sim E., Payton M., Noble M., Minchin R- // Hum. Mol. Genet. 2000. — V. 9, N. 16.-P- 2435 — 2441.
- Sim E. Arylamine N-acetyltransferases: structural and functional?: implications of polymorphisms / Sim E., Lack N., Wang C.J., Long 11., Westwood I., Fullam E., Kawamura A. // Toxicology. 2008. — V. 254, N. 3. — P. 170 — 183.
- Sipes I.G., Gandolfi A.J. Biotransformation of toxicants // Casarett and Doull’s toxicology New York, Macmillan Publishing Company — 1986. — P. 99 — 173.
- Steele M.A. The role of pyrazinamide in tuberculosis chemotherapy / Steele M.A., Des Prez R.M. // Chest. 1988. — V. 94, N. 4. — P. 845 — 850.
- Strolin Benedetti M. Induction and autoinductionproperties of rifamycin derivatives: a review of animal and human studies / Strolin Benedetti M., Dostert P. // Environ: Health Perspect. 1994. — V. 102, Suppl. 9. — P. 101 — 105.
- Sturgill M.G. Xenobiotic-induced hepatotoxicity: mechanisms of liver injury and methods of monitoring hepatic function / Sturgill M.G., Lambert G.H. // Clin. Chem. 1997. — V. 43, N. 8, Pt. 2.-P. 1512 — 1526.
- Svensson C.K. Effects of chloroquine and primaquine on rat liver cytosolic N-acetyltransferase activity / Svensson C.K., Drobitch R.K., Tomilo M. // Biochem. Pharmacol. 1991. — V. 42, N. 4. — P. 954 — 956.
- Tafazoli S. Role of hydrazine in isoniazid-induced hepatotoxicity in a hepatocyte inflammation model / Tafazoli S., Mashregi M., O’Brien P.J. // Toxicol. Appl. Pharmacol. 2008. — V. 229, N. 1. — P. 94 — 101.
- Tang K. The Pstl/Rsal and Dral polymorphisms of CYP2E1 and head and neck cancer risk: a meta-analysis based on 21 case-control studies / Tang K., Li Y., Zhang Z., Gu Y» Xiong Y., Feng G., He L., Qin S. // BMC Cancer. 2010. — V. 10. — P. 575−582.
- Tayal V. Hepatoprotective effect of tocopherol against isoniazid and rifampicin induced hepatotoxicity in albino rabbits / Tayal V., Kalra B.S., Agarwal S., Khurana N., Gupta U. // Indian J. Exp. Biol. 2007. — V. 45, N. 12. — P: 1031 — 1036.
- Teleman M.D. Hepatotoxicity of tuberculosis chemotherapy under general programme conditions in Singapore. / Teleman M.D., Chee C.B., Earnest A., Wang Y.T. // Int. J. Tuberc. Lung Dis. 2002. — V. 6, N. 8. — P. 699 — 705.
- Tetlow N. Functional polymorphism of human glutathione transferase A2 / Tet-low N., Board P.G. // Pharmacogenetics. 2004. — V. 14, N. 2. — P. 111 — 116.
- Tetlow N. Polymorphism of human Alpha class glutathione transferases / Tetlow N., Liu D., Board P. // Pharmacogenetics. 2001. — V. 11, N. 7. — P. 609 — 617.
- Thomas B.H. Effect of rifampin, phenobarbital pretreatment, and acetylator phe-notype on acetylisoniazid metabolism in the rabbit / Thomas B.H., Zeitz W., White-house L.W. // Can. J. Physiol. Pharmacol. 1987. -V. 65, N. 3. — P. 419 — 423.
- Timbrell J.A. Isoniazid hepatoxicity: the relationship between covalent binding and metabolism in vivo / Timbrell J.A., Mitchell J.R., Snodgrass W.R., Nelson S.D. // J. Pharmacol. Exp. Ther. 1980. — V. 213, N. 2. — P. 364 — 369.
- Tomalik-Scharte D: The clinical role of genetic polymorphisms in drug-metabolizing enzyme / Tomalik-Scharte D., Lazar A., Fuhr U., Kirchheiner J. // Pharmacogenomics J. 2008. — V. 8, N. 1. — P. 4 — 15.
- Walubo A. The effect of isoniazid containing regimen on CYP2E1 during antituberculosis therapy / Walubo A'., Coetsee C., Arti D, Du Plessis J.B. // Res. Commun. Mol. Pathol. Pharmacol. 2005. — V. 117 — 118. — P. 137 — 151.
- Walubo A. The role of oxygen free radicals in isoniazid-induced hepatotoxicity / Walubo A., Smith P., Folb Pit // Methods Find. Exp. Clin. Pharmacol. 1998. — V. 20, N. 8-P. 649−655.
- Wang J. IL-4-mediated transcriptional regulation of human CYP2E1 by two independent signaling pathways / Wang J., Hu Y., Nekvindova J., Ingelman-Sundberg M., Neve E.P. // Biochem. Pharmacol. 2010. — V. 80, N. 10. — P. 1592 — 1600. s
- Wang T. Association of P450−2E1 and GSTM1 genetic polymorphisms withsusceptibility to antituberculosis drug-induced hepatotoxicity / Wang T., Wang W.,
- Wang Z.Y., Pan Y.Y., Su Q.Q., He L.X. // Zhonghua Jie. He. He. Hu. Xi. Za. Zhi. -2009. V. 32, N. 8. — P. 585 — 587.
- Watanabe J. Different regulation and expression of the human CYP2E1 gene due to the Rsal polymorphism in the 5'-flanking region / Watanabe J., Hayashi S., Kawa-jiri K. // J Biochem. 1994. — V. 116, N. 2. — P. 321 — 326.
- Weiner I.M. Pharmacology of pyrazinamide: metabolic and renal function studies related to the mechanism of drug-induced urate retention / Weiner I.M., Tinker J.P. // J. Pharmacol. Exp. Ther. 1972. — V. 180, N. 2. — P. 411 — 434.
- Wen X. Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes / Wen X., Wang J.S., Neu-vonen P: J., Backman J.T. // Eur. J. Clin. Pharmacol. 2002. — V. 57, N. 11. — P. 799 -804.
- Wilkins J.J. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients / Wilkins J.J., Langdon G., Mcllleron H., Pillai
- G.C., Smith P.J., Simonsson U.S. // Eur. J. Clin. Pharmacol. 2006. — V. 62, N. 9 -P. 727 — 735.
- Wong W.M. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection / Wong W.M., Wu P.C., Yuen M.F., Cheng C.C., Yew W.W., Wong P.C., Tam C.M., Leung C.C., Lai C.L. // Hepatology. 2000. — V. 31, N. 1. — P. 201 -206.
- Wu D. Ethanol cytotoxicity to a transfected HepG2 cell line expressing human-cytochrome P4502E1 / Wu D., Cederbaum A.I. // J. Biol. Chem. 1996. — V. 271, N. 39-P. 23 914−23 919.
- Yew W.W. Antituberculosis drugs and hepatotoxicity / Yew W.W., Leung C.C. // Respirology. 2006. — V. 11, N. 6. — P. 699 — 707.
- Younossian A.B. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis / Younossian A.B., Rochat T., Ketterer J.P., Wacker J., Janssens J.P. // Eur. Respir. J. 2005. — V. 26, N. 3. — P. 462 — 464.
- Yue J. Effects of rifampin on CYP2E1 -dependent hepatotoxicity of isoniazid in rats / Yue J., Peng R., Chen J., Liu Y., Dong G. // Pharmacol. Res. 2009. — V. 59, N. 2.-P. 112−119.
- Zhang Y. The curious characteristics of pyrazinamide: a review1/ Zhang Y.,. Mitchison D. // Int. J. Tuberc. Lung Dis. 2003. — V. 7, N. 1. — P. 6 — 21.